Journal Article

Effect of Cessation of Highly Active Antiretroviral Therapy during a Discordant Response: Implications for Scheduled Therapeutic Interruptions

Nanci Hawley-Foss, Georgina Mbisa, Julian J. Lum, André A. Pilon, Jonathan B. Angel, Gary Garber and Andrew D. Badley

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 33, issue 3, pages 344-348
Published in print August 2001 | ISSN: 1058-4838
Published online August 2001 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/321902
Effect of Cessation of Highly Active Antiretroviral Therapy during a Discordant Response: Implications for Scheduled Therapeutic Interruptions

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Although treatment with combination antiretroviral therapy leads to a reduction in the level of plasma viremia and an improvement in CD4 T cell count for most patients, for a minority of patients, an improvement in CD4 T cell count occurs despite the failure of treatment to suppress viral replication. Recent reports suggest that these discordant improvements in CD4 T cell count may last for months to years and are associated with improved clinical outcomes. In a retrospective observational study, we evaluated the effect of therapy cessation on 8 patients with discordant immunologic responses to therapy and found that improved CD4 T cell responses are dependent upon ongoing drug pressure. If antiretroviral agents that are likely to resuppress the virus are not available, we suggest that patients continue the therapy associated with immunologic improvement to maximize the clinical benefit of the discordant response.

Journal Article.  2517 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.